Search Results
RG108 5 mg | 99.78%
TargetMol
Fexinidazole 10 mg | 99.79%
TargetMol

Fexinidazole is an antiparasitic agent. It has activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.
More Information Supplier PageFexinidazole 5 mg | 99.79%
TargetMol

Fexinidazole is an antiparasitic agent. It has activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.
More Information Supplier Page2,3-Butanedione 2-Monoxime 100 mg | 99.83%
TargetMol

2, 3-Butanedione 2-Monoxime is an inhibitor of skeletal and cardiac muscle contraction.
More Information Supplier PageCinaciguat 50 mg | Purity Not Available
TargetMol

Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in Clinicalal development for acute decompensated heart failure.
More Information Supplier PageCinaciguat 2 mg | Purity Not Available
TargetMol

Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in Clinicalal development for acute decompensated heart failure.
More Information Supplier PageCinaciguat 10 mg | Purity Not Available
TargetMol

Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase (sGC) activators in Clinicalal development for acute decompensated heart failure.
More Information Supplier Page3-AP 5 mg | 99.05%
TargetMol

3-AP (Triapine) is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR).
More Information Supplier Page3-AP 50 mg | 99.05%
TargetMol

3-AP (Triapine) is a novel inhibitor of the M2 subunit of ribonucleotide reductase (RR).
More Information Supplier Page